Literature DB >> 16702890

Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.

Jonathan Davidson1, Barbara O Rothbaum, Phebe Tucker, Gregory Asnis, Isma Benattia, Jeff J Musgnung.   

Abstract

This 12-week, double-blind, multicenter trial evaluated the efficacy of venlafaxine extended release (ER), sertraline, and placebo in adult outpatients (N = 538) with a primary diagnosis of posttraumatic stress disorder (PTSD), as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, symptoms for 6 months or more and 17-item Clinician-administered PTSD Scale (CAPS-SX17) score of 60 or more. Patients were randomly assigned to receive placebo or flexible doses of venlafaxine ER (37.5-300 mg/d) or sertraline (25-200 mg/d) for 12 weeks or less. The primary outcome was the baseline-to-end point change in total CAPS-SX17 score (last observation carried forward). Secondary measures included CAPS-SX17 symptom cluster scores for reexperiencing/intrusion, avoidance/numbing, and hyperarousal; frequency of remission (CAPS-SX17 < or =20); and changes in Davidson Trauma Scale total score and symptom cluster scores for avoidance/numbing, hyperarousal, and reexperiencing/intrusion. Mean changes in CAPS-SX17 scores were -41.8, -39.4, and -33.9 for venlafaxine ER (P < 0.05 vs. placebo), sertraline, and placebo, respectively. Mean changes for venlafaxine ER, sertraline, and placebo in CAPS-SX17 cluster scores were -13.0, -11.7, and -11.0 for reexperiencing; -17.1, -16.8, and -13.7 (P < 0.05 both active treatments vs. placebo) for avoidance/numbing; and -11.8, -10.9, and -9.2 (P < 0.05 venlafaxine vs. placebo) for hyperarousal. Week 12 remission rates were venlafaxine ER 30.2% (P < 0.05 vs. placebo), sertraline 24.3%, and placebo 19.6%. The venlafaxine ER group had significantly better Davidson Trauma Scale total and cluster scores than placebo. Mean maximum daily doses were 225-mg venlafaxine ER and 151-mg sertraline. Both treatments were generally well tolerated. Study results suggest that venlafaxine ER is effective and well tolerated in the short-term treatment of PTSD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702890     DOI: 10.1097/01.jcp.0000222514.71390.c1

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  36 in total

1.  Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents.

Authors:  Walter Alexander
Journal:  P T       Date:  2012-01

Review 2.  Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.

Authors:  Philippe Yves Rémy Simon; Pierre-François Rousseau
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

3.  Preclinical evaluation of reconsolidation blockade by clonidine as a potential novel treatment for posttraumatic stress disorder.

Authors:  Karine Gamache; Roger K Pitman; Karim Nader
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

Review 4.  Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder.

Authors:  Alexander Neumeister; Jordan Seidel; Benjamin J Ragen; Robert H Pietrzak
Journal:  Psychoneuroendocrinology       Date:  2014-10-22       Impact factor: 4.905

Review 5.  Psychopharmacological strategies in the management of posttraumatic stress disorder (PTSD): what have we learned?

Authors:  Nancy C Bernardy; Matthew J Friedman
Journal:  Curr Psychiatry Rep       Date:  2015-04       Impact factor: 5.285

Review 6.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

7.  Enhancing clinical trial design of interventions for posttraumatic stress disorder.

Authors:  Andrew C Leon; Lori L Davis
Journal:  J Trauma Stress       Date:  2009-12

8.  Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial.

Authors:  Changsu Han; Chi-Un Pae; Bun-Hee Lee; Young-Hoon Ko; Prakash S Masand; Ashwin A Patkar; Sook-Haeng Joe; In-Kwa Jung
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 9.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

Review 10.  Post-traumatic stress disorder: emerging concepts of pharmacotherapy.

Authors:  Dewleen G Baker; Caroline M Nievergelt; Victoria B Risbrough
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.